SCINTIMAMMOGRAPHY - THE COMPLEMENTARY ROLE OF TC-99M SESTAMIBI PRONE BREAST IMAGING FOR THE DIAGNOSIS OF BREAST-CARCINOMA

被引:190
作者
KHALKHALI, I
CUTRONE, JA
MENA, IG
DIGGLES, LE
VENEGAS, RJ
VARGAS, HI
JACKSON, BL
KHALKHALI, S
MOSS, JF
KLEIN, SR
机构
[1] UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT RADIOL,DIV NUCL MED,TORRANCE,CA 90509
[2] UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT SURG,TORRANCE,CA 90509
[3] UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT PATHOL,TORRANCE,CA 90509
[4] UNIV CALIF LOS ANGELES,HARBOR RES & EDUC INST,TORRANCE,CA
关键词
BREAST NEOPLASMS; DIAGNOSIS; RADIONUCLIDE STUDIES;
D O I
10.1148/radiology.196.2.7617855
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To evaluate the complementary role of technetium-99m sestamibi scintimammography in improvement of the sensitivity and specificity of mammography in detection of carcinoma of the breast. MATERIALS AND METHODS: At 5 and 60 minutes after intravenous injection of Tc-99m sestamibi, scintimammograms were obtained in 147 women (age range, 18-73 years; mean age, 47.9 years +/- 10.2 [standard deviation]) with 153 lesions that warranted breast biopsy (102 lesions) or fine-needle aspiration cytologic analysis (51 lesions). There were 113 palpable and 40 nonpalpable lesions. Lesion size on mammograms was 0.8 x 0.6 cm to 15.0 x 11.0 cm (mean, 2.82 cm +/- 1.71 x 2.39 cm +/- 1.56). RESULTS: Scintimammographic findings were true-positive in 47 biopsy-confirmed carcinomas, true-negative in 91 benign lesions, false-positive in 11 lesions with benign histopathologic findings (fibrocystic disease [n = 8] or fibroadenoma [n = 3]), and false-negative in four lesions of infiltrating ductal carcinoma. The sensitivity of scintimammography was 92.2%; specificity, 89.2%; positive predictive value, 81.0%; and negative predictive value, 95.8%. CONCLUSION: The authors conclude that scintimammography is a sensitive test that can improve the detection of breast carcinoma.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 27 条
[1]  
BALON HR, 1992, J NUCL MED, V33, P1393
[2]  
BUCHANAN JB, 1983, RADIOL CLIN N AM, V21, P115
[3]  
BUTLER JA, 1990, ARCH SURG-CHICAGO, V125, P893
[4]  
CANER B, 1992, J NUCL MED, V33, P319
[5]  
CANER B, 1991, J NUCL MED, V32, P1977
[6]  
CARVALHO PA, 1992, J NUCL MED, V33, P1516
[7]  
DELMONMOINGEON LI, 1990, CANCER RES, V50, P2198
[8]  
Diggles L., 1994, Journal of Nuclear Medicine Technology, V22, P165
[9]  
DIGGLES L, 1994, EUR J NUCL MED S10, V21, P101
[10]  
DONNEGAN WL, 1992, NEW ENGL J MED, V327, P937